Enhancing targeted radionuclide therapy with nanoparticles
Debjani Pal, PhD, Oak Ridge National Laboratory, Oak Ridge, TN, discusses the emergence of targeted radionuclide therapy (TRT) for personalized cancer treatment by delivering radiation specifically to cancer cells. Among radioisotopes, actinium-225 shows great potential due to its multiple α-particle emission and high cytotoxicity. Functionalized nanoparticle surfaces enhance biocompatibility and enable conjugation to target cancer cells. Cellular uptake analysis reveals nuclear localization, indicating effective delivery. By incorporating cancer-targeting ligands, these nanoparticles achieve higher efficiency in delivering radioisotopes to tumor cells, demonstrated by effective killing of breast cancer spheroids. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.